Tuesday, October 2, 2012

EASD - Early Data on Canagliflozin from CANVAS Study at EASD

Early data from an 18-week sub-study of 1,718 patients enrolled in CANVAS who were receiving insulin for an average of 7.1 years shows that patients randomized to canagliflozin (100mg and 300mg) in addition to their regular insulin regimen, had statistically greater
A1C reductions at 18 weeks relative to placebo (percent change from baseline, -0.65 and -0.73%, respectively, p < 0.001).
The overall incidence of treatment-emergent adverse events (AEs) was generally similar across all treatment arms.
 CANVAS (CANagliflozin cardioVascular Assessment Study) study is a prospective, double blind, placebo-controlled trial designed to evaluate the efficacy, tolerability and cardiovascular safety of canagliflozin in 4,330 adult patients with type 2 diabetes considered at elevated risk for cardiovascular disease.